Dr. Weldon A. Mauney III, M.D.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
400 Gulf Breeze Pkwy Ste 300
Gulf Breeze, FL 32561
Who else practices at this address →
Santa Rosa County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 38
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
FL license ME105468 -
Specialist
FL license ME105468
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Child Neurology Center of Northwest Florida PA (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 38
- Services billed
- 13,526
- Patients’ average age
- 52
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 12,170 | 22 |
| Injection, baclofen, 10 mg | 166 | 11 |
| Ultrasonic guidance for needle placement | 53 | 20 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 45 | 17 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 36 | 12 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 34 | 15 |
| Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | 29 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 17 companies reported 47 payments worth $1,166 in total to this clinician.
| UCB, Inc. | $448 |
|---|---|
| Jazz Pharmaceuticals Inc. | $153 |
| Acadia Pharmaceuticals Inc | $88.01 |
| Otter Pharmaceuticals, LLC | $69.57 |
| Sk Life Science, Inc. | $62.51 |
| AbbVie Inc. | $54.42 |
| Livanova USA, Inc. | $46.77 |
| Merz Pharmaceuticals, LLC | $37.99 |
| Food and Beverage | $1,166 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $312,567 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OA…
Amgen Inc. - A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company · Active, not recruiting · NCT04616326 - A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05164172 - Study name not reported
Sarepta Therapeutics, Inc. - A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A S · Recruiting · NCT04965675 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc. · Recruiting · NCT05711394 - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine
Merz Pharmaceuticals, LLC - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie Inc. - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc. - A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05897320
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.